Zacks Investment Research
29 Jan 2026, 18:20 UTC · 33w ago
Verdict
Headline leans bullish. We score CNMD +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
CONMED Corporation reported Q4 2025 adjusted EPS of $1.43, beating the Zacks Consensus Estimate by 8.6%.
More positive than 76% of claims this week
CONMED's Q4 revenues rose 7.9% year-over-year to $373.2 million, exceeding consensus estimates by 1.9%.
Continue reading
5 related stories
More positive than 83% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 62% of claims this week
International revenues for CONMED grew 17% on a reported basis, significantly outpacing the 1.4% growth in domestic revenues.
More positive than 49% of claims this week
U.S. General Surgery sales declined by 0.4%, primarily attributed to OEM smoke evacuation SKUs.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company beat earnings and revenue estimates for Q4 2025 and reported adjusted EPS growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
+17.4%
Price agrees with the score
$45.42 vs $38.69 close before publication (Jan 28) · not market-adjusted
CNMD chart →
